AGP Executive Report
Last update: 8 hours agoDrug Approvals: China approved HUTCHMED’s sovleplenib for two antibody-related blood disorders; in a trial for warm autoimmune hemolytic anemia, 66% of patients responded, compared with 15% on placebo. Medicine Access & Deals: China added a record 51 innovative drugs to its reimbursement list, though hospital access remains a hurdle. Guangzhou Innogen signed a diabetes-drug licensing deal worth more than $1 billion, while Pfizer agreed to license autoimmune CAR-T therapies from China’s Starna in a deal worth up to $2.6 billion. Biotech Oversight: Chinese gene-therapy researchers were fired after an investigation into a child’s death, sharpening questions about clinical safeguards. Local Production: Roche completed a $300 million Shanghai plant and plans to make an eye drug there by 2028. Traditional Medicine: WHO experts met in Hong Kong to develop international quality standards for herbal medicines, including guidance on biodiversity and sustainable use.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.